bêta
IA Trial Radar
L'essai clinique NCT02893397 pour Malignant Bone Neoplasm est actif, pas en recrutement. Consultez la vue en carte du Radar des Essais Cliniques et les outils de découverte par IA pour tous les détails, ou posez vos questions ici.
Un essai clinique correspond aux filtres sélectionnés
Vue en carte

Supervised Exercise in Improving Physical Fitness Before Surgery in Patients With Resectable Bone Cancer

Actif, pas en recrutement
Les détails de l'essai clinique sont principalement disponibles en anglais. Cependant, l'IA Trial Radar peut vous aider ! Cliquez simplement sur 'Expliquer l'essai' pour voir et discuter des informations sur l'essai dans la langue sélectionnée.
L'étude clinique NCT02893397 est un essai interventionnel pour Malignant Bone Neoplasm. Son statut actuel est : actif, pas en recrutement. L'étude a débuté le 30 août 2016 et vise à recruter 45 participants. Dirigé par le Centre médical MD Anderson, l'essai devrait être terminé d'ici le 30 août 2026. Les données du site ClinicalTrials.gov ont été mises à jour pour la dernière fois le 5 septembre 2025.
Résumé succinct
This clinical trial studies how well supervised exercise works in improving physical fitness before surgery in patients with bone cancer that can be removed by surgery. Supervised exercise may provide better short-term physical fitness in patients with bone cancer.
Description détaillée
PRIMARY OBJECTIVES:

I. To determine if regular exercise, which may improve delivery and efficacy of chemotherapy, is feasible in children and young adults with malignant bone tumors undergoing neoadjuvant chemotherapy.

SECONDARY OBJECTIVES:

I. To determine if exercise results in a change in tumor vascularity as evidenced by magnetic resonance imaging (MRI) in children and young adults with malignant bone tumors who participate in structured aerobic exercise as compared to children and young adults who do not.

II. To determine whether serum levels of thrombospondin-1, an endogenous anti-angiogenic protein, and sphingosine-1-phosphate, an angiogenic modulator, increase in children and young adults with malignant bone tumors who participate in supervised aerobic exercise over a 4 week period of time during neoadjuvant chemotherapy.

III. To determine if aerobic exercise decreases reactive oxygen species (ROS) in the peripheral blood of bone sarcoma patients.

IV. To determine if the numbers of circulating tumor cells decrease in patients who participate in supervised exercise over a 4 week period of time.

V. To determine whether a home-based exercise program or supervised exercise program is more feasible for this patient population.

OUTLINE: Patients are assigned to 1 of 2 groups.

GROUP I: Patients wear a fitbit and undergo supervised physical therapy exercise sessions over 40 minutes 3-5 times a week for at least 4 weeks.

GROUP II: Patients wear a fitbit.

Titre officiel

Pre-Surgical Supervised Exercise for Bone Cancer Patients

Conditions
Malignant Bone Neoplasm
Autres identifiants de l'essai
Numéro NCT
Date de début (réel)
2016-08-30
Dernière mise à jour publiée
2025-09-05
Date de fin (estimée)
2026-08-30
Inscription (estimée)
45
Type d'essai
Interventionnel
PHASE
N/A
Statut
Actif, pas en recrutement
Objectif principal
Soins de soutien
Plan d'attribution
Non aléatoire
Modèle d'intervention
Parallèle
Bras / Interventions
Groupe de participants/BrasIntervention/Traitement
ExpérimentalGroup I (supervised exercise)
Patients wear a fitbit and undergo supervised physical therapy exercise sessions over 40 minutes 3-5 times a week for at least 4 weeks.
Intervention par l'exercice
Undergo supervised exercise sessions
ExpérimentalGroup II (fitbit)
Patients wear a fitbit.
Activity Monitor
Wear a fitbit
Critère principal d'évaluation
Critères d'évaluationDescription de critèresPériode
Feasibility defined as at least 10 of out 15 patients in the supervised exercise group complete more than or equal to 75% (9 of 12 sessions) supervised physical therapy exercise sessions
Completion of daily exercise is defined as at least 20 minutes of aerobic exercise achieved within heart rate and blood pressure that the licensed physical therapist has determined is safe for the patient on that given day.
At least 4 weeks
Critère secondaire d'évaluation
Critères d'évaluationDescription de critèresPériode
Change in tumor vascularity as measured by magnetic resonance imaging diffusion studies
Will use a two-sided t-test with a significance level of 5% to compare the tumor vascularity between groups.
Baseline up to 4 weeks
Change in tumor vascularity as measured by blood serum analysis of serum thrombospondin-1 and sphingosine-1-phosphate
Will use a two-sided t-test with a significance level of 5% to compare the tumor vascularity between groups.
Baseline up to 4 weeks
Critères d'éligibilité

Âges éligibles
Enfant, Adulte
Âge minimum
5 Years
Sexes éligibles
Tous
  • Patients must have a new diagnosis of primary bone tumor, and whose treatment plan includes surgery
  • Patients who are expected to receive at least 4 weeks of neoadjuvant chemotherapy treatment between enrollment in the study and planned surgery
  • Participants willing to wear a Fitbit

  • Patients who are not receiving their primary cancer care (surgery and chemotherapy) at MD Anderson Cancer Center (participants from the supervised exercise group only)
  • Patients who have a cognitive disorder which impacts the ability to follow directions or adhere to safety rules; this will be determined by the physical therapist by assessing whether a neurological disorder or musculoskeletal disorder would prevent the patient from safely exercising
  • Patients who have a neurological or structural disorder which would impact use of exercise equipment; this will be determined by the physical therapist by assessing whether a neurological disorder or musculoskeletal disorder would prevent the patient from safely exercising
  • Any patient who, in the opinion of the investigators, will be unable to comply with a supervised exercise regimen
  • Any concurrent co-morbid illness and/or infection which in the opinion of the investigators could make the patient unable to comply fully with the trial procedures
M.D. Anderson Cancer Center logoCentre médical MD Anderson1128 essais cliniques actifs à explorer
National Cancer Institute (NCI) logoInstitut national du cancer, États-Unis3039 essais cliniques actifs à explorer
Aucune donnée de contact disponible
2 Centres de l'essai dans 1 pays

Texas

M D Anderson Cancer Center, Houston, Texas, 77030, United States
Texas Children's Hospital, Houston, Texas, 77030, United States